These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28000523)

  • 21. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.
    Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL
    J Clin Invest; 2011 Oct; 121(10):4106-17. PubMed ID: 21926469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation.
    Taki M; Abiko K; Baba T; Hamanishi J; Yamaguchi K; Murakami R; Yamanoi K; Horikawa N; Hosoe Y; Nakamura E; Sugiyama A; Mandai M; Konishi I; Matsumura N
    Nat Commun; 2018 Apr; 9(1):1685. PubMed ID: 29703902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting both tumour-associated CXCR2
    Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
    Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
    Luedke E; Jaime-Ramirez AC; Bhave N; Carson WE
    J Immunother; 2012 Jun; 35(5):367-73. PubMed ID: 22576341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.
    Parseghian CM; Patnana M; Bhosale P; Hess KR; Shih YT; Kim B; Kopetz S; Overman MJ; Varadhachary GR; Javle M; Naing A; Piha-Paul S; Hong D; Le H; Subbiah V; Pant S
    J Immunother; 2018; 41(6):284-291. PubMed ID: 29668571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CXCR2--the receptor to hit?
    Reutershan J
    Drug News Perspect; 2006 Dec; 19(10):615-23. PubMed ID: 17299604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer.
    Vonderheide RH; Bear AS
    Front Immunol; 2020; 11():605619. PubMed ID: 33304355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloid-derived suppressor cells and their role in pancreatic cancer.
    Pergamo M; Miller G
    Cancer Gene Ther; 2017 Mar; 24(3):100-105. PubMed ID: 27910857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which checkpoint inhibitor? An embarrassment of riches for bladder cancer.
    Gill DM; Sonpavde G; Pal SK; Agarwal N
    Immunotherapy; 2017 May; 9(6):463-466. PubMed ID: 28472906
    [No Abstract]   [Full Text] [Related]  

  • 30. Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy.
    Maloney E; Khokhlova T; Pillarisetty VG; Schade GR; Repasky EA; Wang YN; Giuliani L; Primavera M; Hwang JH
    Int Rev Immunol; 2017 Nov; 36(6):338-351. PubMed ID: 28961038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.
    Chung JS; Ramani V; Kobayashi M; Fattah F; Popat V; Zhang S; Cruz PD; Gerber DE; Ariizumi K
    Clin Cancer Res; 2020 Mar; 26(6):1449-1459. PubMed ID: 31822499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-CTLA-4 therapy for malignant mesothelioma.
    Guazzelli A; Bakker E; Krstic-Demonacos M; Lisanti MP; Sotgia F; Mutti L
    Immunotherapy; 2017 Mar; 9(3):273-280. PubMed ID: 28231719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.
    Yang J; Yan C; Vilgelm AE; Chen SC; Ayers GD; Johnson CA; Richmond A
    Cancer Immunol Res; 2021 Feb; 9(2):200-213. PubMed ID: 33177110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
    Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J
    Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic Values of CD38
    Zhang M; Yang J; Zhou J; Gao W; Zhang Y; Lin Y; Wang H; Ruan Z; Ni B
    Immunol Invest; 2019 Jul; 48(5):466-479. PubMed ID: 30689488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
    Amedei A; Niccolai E; Prisco D
    Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer.
    Hashimoto A; Handa H; Hata S; Tsutaho A; Yoshida T; Hirano S; Hashimoto S; Sabe H
    Cell Commun Signal; 2021 May; 19(1):54. PubMed ID: 34001163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases.
    Boppana NB; Devarajan A; Gopal K; Barathan M; Bakar SA; Shankar EM; Ebrahim AS; Farooq SM
    Exp Biol Med (Maywood); 2014 May; 239(5):509-18. PubMed ID: 24625439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.
    Bazhin AV; von Ahn K; Fritz J; Bunge H; Maier C; Isayev O; Neff F; Siveke JT; Karakhanova S
    Oncoimmunology; 2022; 11(1):2043037. PubMed ID: 35251770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
    Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.